Research Article

Epigenetic Regulation and Therapeutic Potential of Gasdermin Genes in Colorectal Adenocarcinoma

Volume: 13 Number: 3 December 28, 2023
EN

Epigenetic Regulation and Therapeutic Potential of Gasdermin Genes in Colorectal Adenocarcinoma

Abstract

Objective: Colorectal adenocarcinoma (COAD) is a complex and lethal cancer characterized by genetic mutations and epigenetic alterations. Gasdermin proteins, such as gasdermin C (GSDMC) and gasdermin D (GSDMD), play crucial roles in pyroptotic cell death, presenting these proteins as potential targets for diagnosis markers and therapy across various cancers, including COAD. Our study investigated the epigenetic regulation of GSDMC and GSDMD in COAD using bioinformatics and in vitro experiments. Materials and Methods: This study examined the expression and epigenetic control of pyroptosis-related proteins in COAD using bioinformatics tools and databases such as Timer2.0, UALCAN, EWAS Open Platform, Gene Set Cancer Analysis (GSCA), Receiver Operating Characteristic (ROC) plotter, and WANDERER. To investigate target gene expression, HTC-116 and SW620 cell lines were subjected to treatments with estrogen, a DNA methylation inhibitor (5-azacytidine), and a histone deacetylase inhibitor (vorinostat). Results: The results showed that the expression of GSDMC and GSDMD varies based on the subtype of COAD. We established that these genes are regulated through DNA hypermethylation in the cg05316065 island for GSDMC and the cg10810860 island for GSDMD. Additionally, the identification of 5-fluorouracil, oxaliplatin, fluoropyrimidine monotherapy, and capecitabine as predictive biomarkers for GSDMC and GSDMD genes underscores the potential clinical utility in cancer therapy. Our results showed that a combined treatment involving 5-azacytidine, vorinostat, and estrogen increases the expression of these genes, potentially guiding cells toward pyroptosis. Conclusions: This comprehensive analysis reveals the complex roles of GSDMC and GSDMD genes in cancer progression, showcasing their susceptibility to epigenetic regulation and impact on chemotherapy responses. These findings offer crucial insights into their significance as potential targets for diagnosis and therapy in cancer, thereby paving the way for personalized treatment strategies.

Keywords

Supporting Institution

Tubitak

Project Number

TUBITAK 2209-A (1919B012209018)

Ethical Statement

Not applicable

Thanks

The authors would like to thank to Caglar Berkel for his assistance.

References

  1. 1. Rawla P, Sunkara T, Barsouk A. Epidemiology of colorectal cancer: incidence, mortality, survival, and risk factors. Prz Gastroenterol 2019; 14(2): 89-103. google scholar
  2. 2. Caldiran FY, Cacan E. RGS10 suppression by DNA methylation is associated with low survival rates in colorectal carcinoma. Pathol Res Pract 2022; 236: 154007. google scholar
  3. 3. Bardhan K, Liu K. Epigenetics and colorectal cancer pathogenesis. Cancers (Basel) 2013; 5(2): 676-713. google scholar
  4. 4. Ashktorab H, Brim H. DNA methylation and colorectal cancer. Curr Colorectal Cancer Rep 2014; 10(4): 425-30. google scholar
  5. 5. Park J, Lee K, Kim K, Yi SJ. The role of histone modifications: from neurodevelopment to neurodiseases. Signal Transduct Target Ther 2022; 7(1): 217. google scholar
  6. 6. Orzolek I, Sobieraj J, Domagala-Kulawik J. Estrogens, cancer and immunity. Cancers 2022; 14(9); 2265. google scholar
  7. 7. Bozovic A, Mandusic V, Todorovic L, Krajnovic M. Estrogen Receptor Beta: The promising biomarker and potential target in metastases. Int J Mol Sci 2021; 22(4): 1656. google scholar
  8. 8. Berkel C, Cacan E. Estrogen- and estrogen receptor (ER)-mediated cisplatin chemoresistance in cancer. Life Sci 2021; 286:20029. google scholar

Details

Primary Language

English

Subjects

Clinical Sciences (Other)

Journal Section

Research Article

Publication Date

December 28, 2023

Submission Date

October 10, 2023

Acceptance Date

November 23, 2023

Published in Issue

Year 2023 Volume: 13 Number: 3

APA
Yıldırımtepe Çaldıran, F., Şenyuva, R., & Çaçan, E. (2023). Epigenetic Regulation and Therapeutic Potential of Gasdermin Genes in Colorectal Adenocarcinoma. Experimed, 13(3), 218-256. https://doi.org/10.26650/experimed.1374173
AMA
1.Yıldırımtepe Çaldıran F, Şenyuva R, Çaçan E. Epigenetic Regulation and Therapeutic Potential of Gasdermin Genes in Colorectal Adenocarcinoma. Experimed. 2023;13(3):218-256. doi:10.26650/experimed.1374173
Chicago
Yıldırımtepe Çaldıran, Feyzanur, Rümeysa Şenyuva, and Ercan Çaçan. 2023. “Epigenetic Regulation and Therapeutic Potential of Gasdermin Genes in Colorectal Adenocarcinoma”. Experimed 13 (3): 218-56. https://doi.org/10.26650/experimed.1374173.
EndNote
Yıldırımtepe Çaldıran F, Şenyuva R, Çaçan E (December 1, 2023) Epigenetic Regulation and Therapeutic Potential of Gasdermin Genes in Colorectal Adenocarcinoma. Experimed 13 3 218–256.
IEEE
[1]F. Yıldırımtepe Çaldıran, R. Şenyuva, and E. Çaçan, “Epigenetic Regulation and Therapeutic Potential of Gasdermin Genes in Colorectal Adenocarcinoma”, Experimed, vol. 13, no. 3, pp. 218–256, Dec. 2023, doi: 10.26650/experimed.1374173.
ISNAD
Yıldırımtepe Çaldıran, Feyzanur - Şenyuva, Rümeysa - Çaçan, Ercan. “Epigenetic Regulation and Therapeutic Potential of Gasdermin Genes in Colorectal Adenocarcinoma”. Experimed 13/3 (December 1, 2023): 218-256. https://doi.org/10.26650/experimed.1374173.
JAMA
1.Yıldırımtepe Çaldıran F, Şenyuva R, Çaçan E. Epigenetic Regulation and Therapeutic Potential of Gasdermin Genes in Colorectal Adenocarcinoma. Experimed. 2023;13:218–256.
MLA
Yıldırımtepe Çaldıran, Feyzanur, et al. “Epigenetic Regulation and Therapeutic Potential of Gasdermin Genes in Colorectal Adenocarcinoma”. Experimed, vol. 13, no. 3, Dec. 2023, pp. 218-56, doi:10.26650/experimed.1374173.
Vancouver
1.Feyzanur Yıldırımtepe Çaldıran, Rümeysa Şenyuva, Ercan Çaçan. Epigenetic Regulation and Therapeutic Potential of Gasdermin Genes in Colorectal Adenocarcinoma. Experimed. 2023 Dec. 1;13(3):218-56. doi:10.26650/experimed.1374173